Prosecution Insights
Last updated: November 18, 2026
Application No. 18/707,825

FORMULATIONS OF PSILOCYBIN ANALOGS AND METHODS OF USE

Non-Final OA §103§112
Filed
May 06, 2024
Priority
Nov 05, 2021 — provisional 63/276,117 +2 more
Examiner
VALENROD, YEVGENY
Art Unit
1628
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Cybin Irl Limited
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
98%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
750 granted / 1033 resolved
+12.6% vs TC avg
Strong +25% interview lift
Without
With
+25.0%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
45 currently pending
Career history
1085
Total Applications
across all art units

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Change of Examiner This application has been reassigned to Examiner Valenrod whose contact information is provided in the conclusion portion of this document. Election/Restrictions Applicant’s election without traverse of Group I, claims 1, 5-7, 10-11, 14-15, 24-26, 28-29, 33-34, 39-40, 45, 51-52, 57, 59-61, 69-70 and 78 in the reply filed on 7/15/26 is acknowledged. Election of compound I-3 as a species for examination is acknowledged. Examiner is interpreting election of I-3 to encompass the salts I-3a, I-3b, I-3c. I-3e and I-3j. Claims 80-84, 89, 92 and 95 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 7/15/26. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 15, 29, 34, 40 and 52 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. The rejected claims are directed to crystal forms of compounds I-3, I-3a, I-3b, I-3c and I-3j characterized by X-ray powder diffraction pattern containing at least three characteristic peaks selected from numerous peaks listed in the claims. Applicants have support for crystal forms of the compounds recited above where all the peaks recited in the claims are present. However, the claims encompass crystal forms that have only three or only four of the listed peaks and not others. There is no evidence that such crystal forms were prepared or that applicant was in possession of non-exemplified polymorphs. Preparation of new crystal forms with predetermined x-ray powder diffraction peaks is not currently possible. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 10 and 11 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The claims recite specific species within the scope of compound of formula (I). The claims also recite “stereoisomer thereof”. Since the recited compounds are not chiral, as lack a stereocenter, it is not clear what the limitation “stereoisomer thereof” refers to. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1, 5-7, 10-11, 14, 24-26, 28, 33, 39, 51, 57, 59-61, 69, 70, 78 is/are rejected under 35 U.S.C. 103 as being unpatentable over Slassi et al (CA 3,166,936; publication date 8/12/21) in view of Chedeayne et al (WO 2018/148605) and Berge et al (Journal of Pharmaceutical Sciences, 1977, 66(1) 1-19). Scope of prior art Slassi teaches compound I-45 or pharmaceutically acceptable sale thereof (page 47). Compound I-45 has the same structure as the elected compound I-3. Slassi also teaches formulating the compound into a composition and various routes of administration (paragraphs [00149]-[00150]). Art teaches adjusting pH of the composition via addition of a buffer. Slassi teaches reconstitution from a solid form (paragraph [00156]). Lastly, in paragraph [00215] Art teaches purification of products using various techniques including recrystallization (last 3 lines). Ascertaining the difference Slassi teaches compound I-45 and pharmaceutically acceptable salts, but fails to recite the anion for the salt. Slassi teaches use of a buffer but does not recite citric acid used as a buffer. Secondary reference Chadeayne teaches preparation of composition comprising psilocin and teaches addition of a buffer to the composition. On page 45, lines 5-12, art teaches addition of a stabilizer, referring to a compound useful for preventing degradation of the active ingredient. As a stabilizer art teaches use of buffers (p 45, line 12). With regards to buffer, art teaches addition of a weak acid and a corresponding conjugate base and lists citric acid as a suitable acid for use as a buffer. (page 45, last paragraph – page 46 lines 1-12). Berge teaches the currently claimed anions as FDA approved anions for pharmaceutical salts (page 2, Table 1). Obviousness A person of ordinary skill in the art, prior to the earliest effective filing date of the current application, would have found it obvious to prepare a pharmaceutical composition comprising compound I-45 of Slassi. Since Slassi teaches both free base and salts of the compound, a skilled artisan would have found it obvious to prepare a composition comprising free base or a salt. While Slassi does not identify which salts to prepare, it would have been obvious to use one of the FDA approved anions taught by Berge as a counterion for the positively charged ammonium ion. A person of ordinary skill would have found it obvious to add a citric acid based buffer to the composition. Chadeayne teaches formulations comprising psilocin based compounds and teaches that a buffer serves as a stabilizer that reduces the degradation of the active agent. Since art describes citric acid can be used as a buffer, a skilled artisan would have found it obvious to add citric acid/citrate buffer with an expectation that degradation of psilocin derivative of Slassi would be reduced. Conclusion Claims 1, 5-7, 10-11, 14-15, 24-26, 28-29, 33-34, 39-40, 45, 51-52, 57, 59-61, 69-70, 78, 80-84, 89, 92 and 95 are pending Claims 1, 5-7, 10-11, 14-15, 24-26, 28-29, 33-34, 39-40, 45, 51-52, 57, 59-61, 69-70 and 78 are rejected Claims 80-84, 89, 92 and 95 are withdrawn Any inquiry concerning this communication or earlier communications from the examiner should be directed to YEVGENY VALENROD whose telephone number is (571)272-9049. The examiner can normally be reached Mon-Fri 9am-5pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Amy L Clark can be reached at 571-272-1310. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /YEVGENY VALENROD/Primary Examiner, Art Unit 1628
Read full office action

Prosecution Timeline

May 06, 2024
Application Filed
Sep 15, 2026
Non-Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788741
METHODS OF TREATMENT
3y 6m to grant Granted Nov 10, 2026
Patent 12788755
METHODS AND COMPOSTITIONS FOR TARGETING PD-L1
2y 9m to grant Granted Nov 10, 2026
Patent 12778970
SUBSTITUTED RESORCYLIC ACID COMPOUNDS AS AMPK ACTIVATOR AND USES THEREOF
3y 6m to grant Granted Nov 03, 2026
Patent 12778924
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DIABETES MELLITUS IN ANIMAL OF FAMILY CANIDAE, COMPRISING ENAVOGLIFLOZIN
2y 11m to grant Granted Nov 03, 2026
Patent 12773402
Use of Chloroquine Compounds for Treatment of Inflammatory Conditions
2y 2m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
98%
With Interview (+25.0%)
Low
PTA Risk
Based on 1033 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month